{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:11:34Z","timestamp":1783771894289,"version":"3.55.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsurgicalresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jss.2026.05.083","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:13:39Z","timestamp":1783768419000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nodal Pathologic Response to Neoadjuvant Systemic Therapy in Clinical N2 and N3 Nonmetastatic Breast Cancer"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4829-8681","authenticated-orcid":false,"given":"Diana M.","family":"Jaen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collin E.","family":"Dougherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"Helseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige A.","family":"Harwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan A.","family":"Santamaria-Barria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7568-6404","authenticated-orcid":false,"given":"Janelle-Cheri","family":"Millen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jss.2026.05.083_bib2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamasurg.2024.5913","article-title":"De-escalation of nodal surgery in clinically node-positive breast cancer","volume":"160","author":"Cab\u0131o\u011flu","year":"2025","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jss.2026.05.083_bib3","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1245\/s10434-025-16973-y","article-title":"Oncologic outcomes with de-escalation of axillary surgery after neoadjuvant chemotherapy for breast cancer: results from > 1500 patients on the I-SPY2 clinical trial","volume":"32","author":"Boughey","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jss.2026.05.083_bib4","article-title":"Feasibility of de-escalating axillary surgery in patients with clinical N2\u20133, pathological N0 breast cancer after neoadjuvant chemotherapy","volume":"15","author":"Kim","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jss.2026.05.083_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1563586","article-title":"Evaluating the survival outcomes in clinical node stage 2 and 3 breast cancer patients with negative sentinel lymph node biopsy after neoadjuvant chemotherapy: sentinel lymph node biopsy alone vs. axillary lymph node dissection","volume":"15","author":"Shin","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.jss.2026.05.083_bib6","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.21.00934","article-title":"Management of the axilla in early-stage breast cancer: Ontario health (Cancer Care Ontario) and ASCO Guideline","volume":"39","author":"Brackstone","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2026.05.083_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjsurg.2024.115893","article-title":"Axillary de-escalation after neoadjuvant chemotherapy for advanced lymph node involvement in breast cancer","volume":"236","author":"Capasso","year":"2024","journal-title":"Am J Surg"},{"key":"10.1016\/j.jss.2026.05.083_bib8","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1245\/s10434-021-09897-w","article-title":"Factors associated with nodal pathologic complete response among breast cancer patients treated with neoadjuvant chemotherapy: results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance)","volume":"28","author":"Weiss","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jss.2026.05.083_bib9","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10549-020-05970-2","article-title":"Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?","volume":"185","author":"Garcia-Tejedor","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jss.2026.05.083_bib10","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jamasurg.2023.1772","article-title":"Safety of targeted axillary dissection after neoadjuvant therapy in patients with node-positive breast cancer","volume":"158","author":"Kuemmel","year":"2023","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jss.2026.05.083_bib11","doi-asserted-by":"crossref","first-page":"8636","DOI":"10.1245\/s10434-021-10195-8","article-title":"Association of tumor molecular subtype and stage with breast and axillary pathologic complete response after neoadjuvant chemotherapy for breast cancer","volume":"28","author":"Myers","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jss.2026.05.083_bib12","doi-asserted-by":"crossref","first-page":"9767","DOI":"10.1245\/s10434-025-17906-5","article-title":"Predictors of nodal pathologic complete response after neoadjuvant chemotherapy in breast cancer","volume":"32","author":"An","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jss.2026.05.083_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2021.0891","article-title":"Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis","volume":"156","author":"Samiei","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jss.2026.05.083_bib14","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/jamasurg.2018.2696","article-title":"Association of low nodal positivity rate among patients with ERBB2 -Positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy","volume":"153","author":"Barron","year":"2018","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jss.2026.05.083_bib15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3390\/cancers14030521","article-title":"Pathological response in the breast and axillary lymph nodes after neoadjuvant systemic treatment in patients with initially node-positive breast cancer correlates with disease free survival: an exploratory analysis of the GeparOcto trial","volume":"14","author":"Gerber","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jss.2026.05.083_bib16","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/SLA.0000000000003126","article-title":"Correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy","volume":"271","author":"Samiei","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.jss.2026.05.083_bib17","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1097\/SLA.0000000000004572","article-title":"A prospective, multicenter registry study to evaluate the clinical feasibility of Targeted Axillary Dissection (TAD) in node-positive breast cancer patients","volume":"276","author":"Kuemmel","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.jss.2026.05.083_bib18","first-page":"1863","article-title":"Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study","volume":"109","author":"Wu","year":"2023","journal-title":"Int J Surg"},{"key":"10.1016\/j.jss.2026.05.083_bib19","doi-asserted-by":"crossref","first-page":"8813","DOI":"10.1245\/s10434-024-16143-6","article-title":"Omission of axillary lymph node dissection in patients with residual nodal disease after neoadjuvant chemotherapy","volume":"31","author":"Limberg","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jss.2026.05.083_bib20","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.breast.2021.09.004","article-title":"Tailored axillary surgery in patients with clinically node-positive breast cancer: pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23\/16, IBCSG 57-18, ABCSG-53, GBG 101)","volume":"60","author":"Weber","year":"2021","journal-title":"Breast"}],"container-title":["Journal of Surgical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002248042600418X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002248042600418X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:13:48Z","timestamp":1783768428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002248042600418X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":19,"alternative-id":["S002248042600418X"],"URL":"https:\/\/doi.org\/10.1016\/j.jss.2026.05.083","relation":{},"ISSN":["0022-4804"],"issn-type":[{"value":"0022-4804","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nodal Pathologic Response to Neoadjuvant Systemic Therapy in Clinical N2 and N3 Nonmetastatic Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Surgical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jss.2026.05.083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}